According to TipRanks.com, Astrachan is a 5-star analyst with an average return of 11.8% and a 63.7% success rate. Astrachan covers the Consumer Goods sector, focusing on stocks such as The Estée Lauder Companies, Reynolds Consumer Products, and Colgate-Palmolive.
Nu Skin has an analyst consensus of Moderate Buy, with a price target consensus of $56.00, which is a 30.0% upside from current levels. In a report issued on May 5, D.A. Davidson also maintained a Hold rating on the stock with a $45.00 price target.
Based on Nu Skin’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $673 million and GAAP net loss of $9.23 million. In comparison, last year the company earned revenue of $748 million and had a net profit of $73.47 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Nu Skin Enterprises, Inc. develops and distributes personal care products and nutritional supplements. The firm engages in the provision of beauty and wellness products and solutions. Its brands include Nu Skin and Pharmanex. The company was founded by Blake M. Roney, Sandra N. Tillotson, and Steven J. Lund in 1984 and is headquartered in Provo, UT.
Read More on NUS:
- Northwest Gas (NWN) Receives a Buy from Stifel Nicolaus
- Stifel Nicolaus Thinks Spirit Realty Capital’s Stock is Going to Recover
- Stifel Nicolaus Sticks to Its Buy Rating for Evoqua Water Technologies (AQUA)
- Stifel Nicolaus Remains a Buy on Werner Enterprises (WERN)
- Stifel Nicolaus Thinks OrthoPediatrics’ Stock is Going to Recover